CEO stepping down

Growth that keeps on growing

Impressive sales growth in Q1

BONESUPPORT: Q1 revenue beats, but FX-driven EBIT miss masks solid mom...

BONESUPPORT reported a robust Q1, with net sales of SEK283.5m beating CSS SEK276m and driven by CERAMENT G sales of SEK178m in North America — well ahead of the SEK160m forecast. Gross margin remained best-in-class at 92.6%, slightly above expectations, underscoring the strength of the business mod

Focus on the organic growth

BONESUPPORT: Model Update – Reiterate BUY and SEK400 PT

We have updated our model, rolling it over after Q4 results and in preparation for Q1 2025, to be reported on 24 April. While our long-term conviction for BONESUPPORT products has not changed, we have slightly softened our 2025 EU sales growth assumptions from 39% to 22% YoY growth following a slow

EU tariff summary for Swedish small caps

The future continues to look good

BONESUPPORT: Closing a solid 2024

2024 saw BONESUPPORT further accelerate its market leadership with Q4 sales reaching SEK257m—up 49% YoY—driving FY sales to SEK898.7m (52% YoY), in line with guidance of 50% topline growth. In North America, CERAMENT G continued its strong performance, rising by approximately SEK22m QoQ to reach ar

Positive outlook for 2025

The growth story continues

BONESUPPORT: CERAMENT adverse event clarification amidst market volati...

BONESUPPORT shares have dropped by 15% YTD, driven by profit-taking ahead of FY 2024 earnings on February 25, coupled with concerns over a reported adverse event involving CERAMENT BVF. We believe the market reaction is overblown, largely fueled by retail sentiment. The event resulted from off-labe

Small Caps, Big Ideas – December 2024

BONESUPPORT: 5-year data positions CERAMENT as a game-changer in DFO m...

Yesterday, during trading hours, BONESUPPORT announced impressive long-term data on CERAMENT's capabilities in managing bone infections associated with diabetic foot ulcers (DFUs), a condition of growing prevalence due to the rising incidence of diabetes. The study, involving 105 patients, demonstr

BONESUPPORT: Increasing conviction, PT raised to SEK400

BONESUPPORT trades at a premium on EV/Sales and EV/EBITDA to peers, yet a valuation justified by its unique market positioning. The company leads the ortho-biologics market without competition for its antibiotic-eluting CERAMENT products. Beyond its proprietary technology, BONESUPPORT consistently

Bonesupport Holding AB: 1 director

A director at Bonesupport Holding AB sold 59,407 shares at 325.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Growth case confirmed

Strong sales growth in the US

BONESUPPORT: CERAMENT G leads strong US growth amid softer EU seasonal...

Q3 2024 followed a similar trend to the first half of the year, with CERAMENT G leading revenue generation. Exceeding expectations, CERAMENT G grew by SEK 25m QoQ in the US, reaching SEK 132m, as the company rapidly secures new hospital agreements. However, CERAMENT BVF saw a slight decline, with U

CERAMENT G to drive growth in Q3